PharmaCorp Rx Inc

PharmaCorp Rx Inc maintains a strong liquidity position, with CAD 25.89 million in cash and equivalents, representing a significant portion of its total assets. The company's debt-to-equity ratio of 0.08 indicates a conservative capital structure, with total liabilities of CAD 13.65 million compared to total equity of CAD 52.27 million. This low leverage supports financial flexibility and reduces exposure to interest rate fluctuations. The company's profitability is reflected in its operating cash flow of CAD 2.01 million, which, while modest, supports ongoing operations and capital expenditures. However, the operating cash flow is relatively low compared to the company's revenue of CAD 20.89 million, suggesting potential inefficiencies or high operating costs. The capital expenditure of CAD -87,600 indicates minimal investment in new assets, which may limit future growth opportunities. PharmaCorp Rx Inc's revenue is concentrated in the drug retailing segment, with no disclosed geographic diversification. This concentration increases the company's vulnerability to regional economic downturns or regulatory changes affecting the pharmaceutical retail market. The lack of geographic diversification is a notable risk factor, as it limits the company's ability to offset losses in one region with gains in another. The company's growth trajectory is modest, with no significant revenue growth reported in the latest financial data. Analysts have set a mean price target of CAD 0.57, with a median of CAD 0.57, indicating a neutral outlook. The absence of strong buy recommendations and the limited number of buy ratings suggest that the market does not anticipate substantial growth in the near term. Risk factors for PharmaCorp Rx Inc include low liquidity and dilution risks, with no immediate filing-based flags detected. The company's low debt levels and strong cash reserves mitigate liquidity concerns. However, the lack of capital expenditures and the conservative capital structure may limit long-term growth potential. The dilution risk is also low, with no significant dilution sources identified in the latest filings. Recent events and filings do not indicate any major changes in the company's operations or financial strategy. The company continues to operate within its established business model, with no significant new product launches or market expansions reported. The absence of recent events suggests a stable but potentially stagnant business environment.